Hospital
University Hospital at Stony Brook
University Hospital at Stony Brook was paid $105.33M by Medicaid between Jan 2018 and Dec 2024, across 535 billing codes. Its largest line is 90791, psychiatric diagnostic evaluation — 12% of everything it billed.
33Billing provider infoUNIVERSITY HOSPITAL AT STONY BROOK
STONY BROOK, NY 11794
STONY BROOK, NY 11794
33aNPI1972523348assigned 07/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$105.33M
24GClaims1,713,835
24DCodes billed535
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#14 of 231
Median peer was paid$561K
This provider vs. median188×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,594 | $641K | |
| 2019 | 106,039 | $6.06M | |
| 2020 | 256,944 | $14.42M | |
| 2021 | 320,210 | $18.05M | |
| 2022 | 338,958 | $22.29M | |
| 2023 | 380,154 | $25.22M | |
| 2024incomplete | 283,936 | $18.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 12% | 13,009 | 11,740 | $13.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.3% | 56,088 | 53,442 | $9.77M |
| G0378 | Hospital observation service, per hour | 7.0% | 12,354 | 11,105 | $7.40M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.4% | 52,323 | 48,476 | $6.75M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.4% | 36,146 | 33,649 | $5.74M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.7% | 34,669 | 33,022 | $4.94M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 18,610 | 18,110 | $3.18M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.1% | 18,629 | 17,250 | $2.22M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.7% | 17,699 | 17,673 | $1.83M |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.6% | 14,437 | 13,706 | $1.65M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 8,863 | 8,598 | $1.51M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 9,598 | 8,504 | $1.46M |
523 more codes
| 93975 | 1.4% | 4,784 | $1.46M | |
| 99285 | Emergency room visit (most serious) | 1.3% | 8,708 | $1.41M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.3% | 12,574 | $1.40M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 7,491 | $1.32M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 2,476 | $1.29M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 91,522 | $1.23M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 8,805 | $1.13M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 3,284 | $1.11M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 11,142 | $1.10M |
| 96415 | <1% | 2,127 | $983K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 7,844 | $936K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13,156 | $911K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,723 | $881K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 635 | $792K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 4,707 | $785K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,288 | $772K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,206 | $734K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,137 | $731K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 308 | $688K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,015 | $679K |
| 92552 | <1% | 9,007 | $654K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,572 | $636K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 864 | $577K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 754 | $552K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,028 | $548K |
| 80076 | <1% | 56,103 | $532K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,882 | $530K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 5,037 | $507K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,194 | $492K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 73 | $479K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,732 | $466K |
| 86850 | <1% | 19,930 | $460K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,181 | $439K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,669 | $424K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 519 | $401K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,087 | $380K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,443 | $361K |
| 76770 | <1% | 1,340 | $361K | |
| 86901 | <1% | 20,663 | $346K | |
| 93970 | <1% | 821 | $345K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,012 | $342K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,686 | $342K |
| 59025 | Fetal non-stress test | <1% | 2,274 | $333K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,847 | $328K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 320 | $317K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,796 | $300K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12,931 | $298K |
| 92550 | <1% | 4,004 | $252K | |
| 86900 | <1% | 20,695 | $252K | |
| 99245 | <1% | 1,338 | $250K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 231 | $243K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,433 | $238K |
| H0037 | Community psychiatric supportive treatment program, per diem | <1% | 449 | $236K |
| 96367 | <1% | 2,326 | $227K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 528 | $221K |
| 92587 | <1% | 4,564 | $218K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,928 | $216K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,478 | $213K |
| 70496 | <1% | 1,221 | $209K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,029 | $189K |
| 12011 | <1% | 612 | $187K | |
| 36430 | <1% | 1,033 | $186K | |
| 97161 | <1% | 1,448 | $183K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,627 | $174K |
| 95813 | <1% | 523 | $169K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,281 | $151K |
| 99381 | <1% | 1,233 | $151K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,099 | $148K |
| 44970 | <1% | 68 | $145K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,516 | $141K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,305 | $131K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 116 | $125K |
| 99243 | <1% | 813 | $123K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 92 | $122K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 741 | $120K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 78,639 | $119K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,207 | $116K |
| 93325 | <1% | 2,816 | $116K | |
| 95816 | <1% | 483 | $115K | |
| 99205 | Prolong outpt/office vis | <1% | 612 | $113K |
| 72082 | <1% | 1,486 | $109K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 625 | $109K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,602 | $107K |
| 73564 | <1% | 2,510 | $104K | |
| 88185 | <1% | 605 | $100K | |
| 0223U | <1% | 5,590 | $99K | |
| 83880 | <1% | 4,421 | $98K | |
| 99383 | <1% | 716 | $98K | |
| 92555 | <1% | 1,704 | $95K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,920 | $94K |
| 73610 | <1% | 4,516 | $92K | |
| 12001 | <1% | 328 | $92K | |
| 86618 | <1% | 4,964 | $91K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,456 | $88K |
| 73630 | <1% | 4,394 | $87K | |
| 92557 | <1% | 1,688 | $85K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,355 | $85K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,207 | $84K |
| 97162 | <1% | 735 | $84K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 436 | $83K |
| 94060 | <1% | 378 | $81K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,150 | $77K |
| 76641 | <1% | 1,242 | $76K | |
| 71250 | <1% | 978 | $75K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,845 | $75K |
| 92579 | <1% | 1,581 | $74K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,412 | $73K |
| 86617 | <1% | 4,358 | $72K | |
| 85610 | <1% | 19,276 | $71K | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 417 | $70K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,469 | $69K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,513 | $68K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 294 | $67K |
| 96132 | <1% | 664 | $66K | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 67 | $64K |
| 92567 | <1% | 1,213 | $63K | |
| 73110 | <1% | 3,014 | $61K | |
| 97010 | <1% | 5,054 | $60K | |
| 88342 | <1% | 1,811 | $60K | |
| 92556 | <1% | 1,369 | $60K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,791 | $59K |
| 99173 | <1% | 2,491 | $58K | |
| 36591 | <1% | 1,292 | $57K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 384 | $57K |
| 99384 | <1% | 393 | $56K | |
| 96116 | <1% | 312 | $55K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,486 | $55K |
| 93320 | <1% | 1,970 | $55K | |
| 88307 | <1% | 906 | $54K | |
| 96127 | <1% | 10,463 | $53K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,677 | $51K |
| 82728 | <1% | 5,053 | $50K | |
| H0049 | Alcohol and/or drug screening | <1% | 2,057 | $50K |
| 73030 | <1% | 2,874 | $50K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 3,091 | $50K |
| 75574 | <1% | 245 | $50K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 8,683 | $50K |
| 70491 | <1% | 230 | $49K | |
| 99385 | <1% | 351 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,660 | $47K |
| 77336 | <1% | 220 | $46K | |
| 93017 | <1% | 365 | $45K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,918 | $44K |
| 87536 | <1% | 501 | $44K | |
| 76000 | <1% | 373 | $43K | |
| 86480 | <1% | 857 | $43K | |
| 93971 | <1% | 1,082 | $42K | |
| 92582 | <1% | 598 | $41K | |
| 86923 | <1% | 1,354 | $41K | |
| 73130 | <1% | 2,622 | $41K | |
| 96409 | <1% | 456 | $40K | |
| 70486 | <1% | 1,042 | $39K | |
| 92610 | <1% | 319 | $38K | |
| 88304 | <1% | 2,321 | $38K | |
| 10060 | <1% | 160 | $38K | |
| 76825 | <1% | 235 | $38K | |
| 83735 | <1% | 32,227 | $37K | |
| 41800 | <1% | 649 | $37K | |
| 95700 | <1% | 434 | $37K | |
| 84702 | <1% | 20,834 | $37K | |
| 88108 | <1% | 1,596 | $37K | |
| 72170 | <1% | 1,503 | $36K | |
| 80061 | Lipid panel | <1% | 5,252 | $36K |
| 72100 | <1% | 762 | $36K | |
| 81513 | <1% | 812 | $36K | |
| 86360 | <1% | 800 | $36K | |
| 73590 | <1% | 2,563 | $36K | |
| 70544 | <1% | 132 | $35K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 269 | $35K |
| 96136 | <1% | 349 | $35K | |
| 73080 | <1% | 2,264 | $35K | |
| D7111 | <1% | 248 | $35K | |
| 82784 | <1% | 2,223 | $34K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,919 | $34K |
| 73502 | <1% | 1,565 | $33K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 661 | $32K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 127 | $32K |
| 81001 | <1% | 33,256 | $31K | |
| 70498 | <1% | 1,124 | $31K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,572 | $31K |
| 80053 | Comprehensive metabolic panel | <1% | 3,022 | $31K |
| 73090 | <1% | 2,306 | $31K | |
| 84466 | <1% | 3,103 | $31K | |
| 85730 | <1% | 17,885 | $31K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 58 | $30K |
| 87481 | <1% | 850 | $30K | |
| 96137 | <1% | 349 | $29K | |
| 83970 | <1% | 725 | $28K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,174 | $27K |
| 82378 | <1% | 2,198 | $27K | |
| 73140 | <1% | 914 | $27K | |
| 85027 | <1% | 14,962 | $26K | |
| 82607 | <1% | 2,727 | $26K | |
| 97802 | <1% | 394 | $26K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,533 | $25K |
| 87799 | <1% | 552 | $25K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,171 | $24K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 46 | $23K |
| 90715 | <1% | 1,351 | $23K | |
| 88341 | <1% | 832 | $23K | |
| 96417 | <1% | 503 | $23K | |
| 73562 | <1% | 2,638 | $22K | |
| 80069 | <1% | 2,448 | $22K | |
| 87631 | <1% | 605 | $21K | |
| 87497 | <1% | 810 | $21K | |
| 83615 | <1% | 6,475 | $21K | |
| 94727 | <1% | 394 | $20K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 990 | $20K |
| 72081 | <1% | 375 | $20K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,757 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,558 | $19K |
| 93458 | <1% | 12 | $19K | |
| 82746 | <1% | 2,241 | $18K | |
| 84100 | <1% | 29,398 | $18K | |
| 86359 | <1% | 814 | $18K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 28 | $18K |
| 77073 | <1% | 412 | $18K | |
| 95811 | <1% | 26 | $17K | |
| 74174 | <1% | 137 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,809 | $17K |
| 83020 | <1% | 1,377 | $16K | |
| 76818 | <1% | 418 | $16K | |
| 94729 | <1% | 415 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 556 | $16K |
| 88184 | <1% | 525 | $16K | |
| 83540 | <1% | 3,476 | $15K | |
| 92551 | <1% | 483 | $15K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 370 | $15K |
| 54161 | <1% | 13 | $15K | |
| 87507 | <1% | 248 | $14K | |
| 86300 | <1% | 892 | $14K | |
| 73552 | <1% | 1,086 | $14K | |
| 29125 | <1% | 94 | $14K | |
| 73560 | <1% | 634 | $14K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 82 | $14K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,462 | $14K |
| 91065 | <1% | 164 | $14K | |
| 52356 | <1% | 12 | $14K | |
| 64400 | <1% | 44 | $13K | |
| 85045 | <1% | 4,794 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 932 | $13K |
| 58558 | <1% | 12 | $13K | |
| 84460 | <1% | 3,283 | $13K | |
| 95782 | <1% | 13 | $13K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 215 | $13K |
| 76827 | <1% | 235 | $12K | |
| 87077 | <1% | 3,961 | $12K | |
| A0425 | Ground mileage, per statute mile | <1% | 1,464 | $12K |
| 84439 | <1% | 2,575 | $12K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 152 | $11K |
| 73000 | <1% | 413 | $11K | |
| 84450 | <1% | 3,263 | $11K | |
| 86140 | <1% | 8,122 | $11K | |
| 99382 | <1% | 103 | $11K | |
| 99386 | <1% | 77 | $11K | |
| 82248 | <1% | 3,619 | $11K | |
| 36416 | <1% | 544 | $11K | |
| 82247 | <1% | 3,512 | $10K | |
| 94010 | <1% | 213 | $10K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 347 | $10K |
| 87070 | <1% | 2,958 | $10K | |
| 20553 | <1% | 38 | $10K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,849 | $10K |
| 73060 | <1% | 1,042 | $10K | |
| 43235 | <1% | 17 | $9K | |
| 84484 | <1% | 14,787 | $9K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 171 | $9K |
| 12002 | <1% | 27 | $9K | |
| 87081 | <1% | 2,518 | $9K | |
| 86769 | <1% | 227 | $9K | |
| C1769 | Guide wire | <1% | 1,145 | $9K |
| 86803 | <1% | 1,669 | $9K | |
| 74230 | <1% | 74 | $8K | |
| 80197 | <1% | 955 | $8K | |
| 96376 | <1% | 5,573 | $8K | |
| 87184 | <1% | 3,054 | $8K | |
| 86304 | <1% | 720 | $8K | |
| 95715 | <1% | 42 | $8K | |
| 96133 | <1% | 129 | $8K | |
| 83690 | <1% | 18,598 | $8K | |
| 76937 | <1% | 55 | $7K | |
| 62321 | <1% | 12 | $7K | |
| 72020 | <1% | 326 | $7K | |
| 82570 | <1% | 2,180 | $7K | |
| 92585 | <1% | 57 | $7K | |
| 0042T | <1% | 170 | $7K | |
| 76870 | <1% | 428 | $7K | |
| 72131 | <1% | 78 | $7K | |
| 88312 | <1% | 273 | $7K | |
| 87186 | <1% | 2,937 | $6K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 8,917 | $6K |
| 77065 | Tomosynthesis, mammo | <1% | 84 | $6K |
| 96523 | <1% | 173 | $6K | |
| 85652 | <1% | 7,986 | $6K | |
| 84550 | <1% | 1,841 | $6K | |
| 70547 | <1% | 37 | $6K | |
| 83010 | <1% | 641 | $6K | |
| 17250 | <1% | 32 | $6K | |
| 72141 | <1% | 26 | $6K | |
| 69210 | <1% | 81 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,462 | $5K |
| 59430 | <1% | 112 | $5K | |
| 81025 | <1% | 2,111 | $5K | |
| 87040 | <1% | 6,257 | $5K | |
| 16020 | <1% | 13 | $5K | |
| 91010 | <1% | 12 | $5K | |
| 83605 | <1% | 9,426 | $5K | |
| 84703 | <1% | 6,268 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,823 | $5K |
| 73070 | <1% | 119 | $5K | |
| 80074 | <1% | 310 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,934 | $5K |
| 93308 | <1% | 13 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 39 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 272 | $4K |
| 82805 | <1% | 645 | $4K | |
| 87468 | <1% | 149 | $4K | |
| 92653 | <1% | 51 | $4K | |
| 72040 | <1% | 159 | $4K | |
| 82150 | <1% | 2,265 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 30 | $4K |
| 99152 | <1% | 576 | $4K | |
| 84156 | <1% | 1,696 | $4K | |
| 86160 | <1% | 211 | $4K | |
| 82550 | <1% | 2,914 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20,598 | $4K |
| 85379 | <1% | 2,950 | $4K | |
| 90686 | <1% | 231 | $4K | |
| 86038 | <1% | 775 | $3K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 260 | $3K |
| 89051 | <1% | 607 | $3K | |
| 96368 | <1% | 156 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 730 | $3K |
| 96411 | <1% | 92 | $3K | |
| 87205 | <1% | 2,714 | $3K | |
| 92526 | <1% | 26 | $3K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 16 | $3K |
| 76604 | <1% | 45 | $3K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,766 | $3K |
| 91037 | <1% | 12 | $3K | |
| 87340 | <1% | 696 | $3K | |
| 74220 | <1% | 24 | $3K | |
| 87484 | <1% | 149 | $2K | |
| 74019 | <1% | 586 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,229 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,576 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,918 | $2K |
| 92002 | <1% | 37 | $2K | |
| 86592 | <1% | 1,665 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,010 | $2K |
| 82310 | <1% | 3,022 | $2K | |
| 82565 | <1% | 3,059 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,198 | $2K |
| 87088 | <1% | 863 | $2K | |
| D9210 | <1% | 267 | $2K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 16 | $2K |
| 84436 | <1% | 674 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 833 | $2K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 1,099 | $2K |
| 83516 | <1% | 181 | $2K | |
| 86880 | <1% | 182 | $2K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 13 | $2K |
| 86870 | <1% | 100 | $2K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 3,551 | $2K |
| 74018 | <1% | 846 | $2K | |
| 84165 | <1% | 270 | $2K | |
| 72110 | <1% | 90 | $2K | |
| 97803 | <1% | 39 | $2K | |
| D9211 | <1% | 358 | $2K | |
| 77003 | <1% | 14 | $1K | |
| 96121 | <1% | 12 | $1K | |
| 86364 | <1% | 214 | $1K | |
| 86706 | <1% | 221 | $1K | |
| 97165 | <1% | 12 | $1K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 183 | $1K |
| 84520 | <1% | 3,037 | $1K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 12 | $1K |
| 92134 | <1% | 13 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 57 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 775 | $1K |
| 76642 | <1% | 29 | $1K | |
| 82374 | <1% | 2,745 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,131 | $1K |
| 99151 | <1% | 85 | $1K | |
| 92060 | <1% | 14 | $999.68 | |
| J3490 | Unclassified drugs | <1% | 3,466 | $998.39 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,143 | $992.98 |
| 84403 | <1% | 72 | $988.16 | |
| 86235 | <1% | 66 | $974.49 | |
| 73700 | <1% | 16 | $937.13 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,278 | $926.36 |
| 92553 | <1% | 14 | $916.59 | |
| 83521 | <1% | 76 | $915.08 | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 55 | $858.55 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,512 | $849.29 |
| 87147 | <1% | 435 | $825.46 | |
| 96402 | <1% | 12 | $816.85 | |
| 82465 | <1% | 524 | $816.41 | |
| 86431 | <1% | 166 | $766.60 | |
| 99499 | <1% | 55 | $763.79 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,668 | $744.43 |
| 86665 | <1% | 124 | $742.10 | |
| 92083 | <1% | 14 | $734.40 | |
| 83001 | <1% | 43 | $728.07 | |
| 84153 | <1% | 53 | $687.09 | |
| 82077 | <1% | 2,889 | $685.91 | |
| 86334 | <1% | 38 | $668.13 | |
| 99417 | Prolong home eval add 15m | <1% | 26 | $661.40 |
| 82043 | <1% | 144 | $660.41 | |
| 82947 | <1% | 2,726 | $653.26 | |
| 93321 | <1% | 26 | $608.67 | |
| 83655 | <1% | 88 | $604.42 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $601.45 |
| 82435 | <1% | 2,744 | $589.68 | |
| 84295 | <1% | 2,758 | $587.96 | |
| 86225 | <1% | 135 | $582.79 | |
| 86258 | <1% | 62 | $571.16 | |
| 86376 | <1% | 76 | $543.59 | |
| 82040 | <1% | 196 | $542.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,990 | $538.39 |
| 73100 | <1% | 17 | $517.79 | |
| J0184 | Injection, amisulpride, 1 mg | <1% | 50 | $510.17 |
| 86328 | <1% | 14 | $483.27 | |
| 86800 | <1% | 65 | $476.90 | |
| 84480 | <1% | 189 | $476.17 | |
| 80143 | <1% | 1,614 | $453.05 | |
| 84145 | <1% | 932 | $445.40 | |
| 86039 | <1% | 113 | $444.09 | |
| 80179 | <1% | 1,561 | $438.29 | |
| 87493 | <1% | 16 | $413.70 | |
| 80180 | <1% | 56 | $400.77 | |
| 97116 | <1% | 31 | $400.34 | |
| 94761 | <1% | 218 | $399.57 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,793 | $385.61 |
| 86580 | <1% | 50 | $382.29 | |
| 99408 | <1% | 31 | $366.36 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,694 | $357.22 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 14 | $352.95 |
| 82670 | <1% | 14 | $346.38 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,053 | $333.22 |
| 88189 | <1% | 12 | $317.18 | |
| 84132 | <1% | 1,471 | $313.80 | |
| 86664 | <1% | 127 | $297.55 | |
| 84112 | <1% | 12 | $289.75 | |
| 87660 | <1% | 25 | $279.00 | |
| 87480 | <1% | 25 | $279.00 | |
| 87510 | <1% | 25 | $279.00 | |
| 85245 | <1% | 25 | $276.55 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 51 | $276.12 |
| 86663 | <1% | 128 | $254.61 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 517 | $252.00 |
| 0097U | <1% | 42 | $246.87 | |
| 85240 | <1% | 18 | $243.55 | |
| 85246 | <1% | 25 | $236.69 | |
| 82977 | <1% | 61 | $211.64 | |
| 86762 | <1% | 12 | $205.49 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 304 | $203.49 |
| 82731 | <1% | 12 | $192.15 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 547 | $191.11 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 552 | $187.59 |
| 99024 | <1% | 153 | $185.12 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 524 | $181.91 |
| 86147 | <1% | 13 | $179.86 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 719 | $169.26 |
| 81003 | <1% | 172 | $162.82 | |
| 87449 | <1% | 95 | $162.56 | |
| C9153 | Injection, amisulpride, 1 mg | <1% | 30 | $157.50 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,652 | $151.89 |
| 90656 | <1% | 19 | $142.25 | |
| 87076 | <1% | 144 | $136.55 | |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 125 | $134.60 |
| 85384 | <1% | 32 | $128.53 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,508 | $123.43 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 401 | $115.53 |
| 82010 | <1% | 650 | $106.47 | |
| 85613 | <1% | 12 | $100.88 | |
| 86787 | <1% | 13 | $86.73 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 100 | $81.00 |
| 87015 | <1% | 277 | $64.33 | |
| 93356 | <1% | 27 | $54.90 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 103 | $52.83 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,536 | $49.75 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 82 | $49.10 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,541 | $45.14 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,619 | $44.94 |
| 80164 | <1% | 57 | $42.11 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,579 | $40.15 |
| 87207 | <1% | 211 | $36.05 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,145 | $32.54 |
| 83930 | <1% | 30 | $30.20 | |
| 86308 | <1% | 170 | $28.15 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 135 | $27.89 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 987 | $26.80 |
| 84300 | <1% | 14 | $24.65 | |
| J7699 | Noc drugs, inhalation solution administered through dme | <1% | 368 | $24.63 |
| 82365 | <1% | 13 | $23.54 | |
| 84479 | <1% | 12 | $23.10 | |
| C1758 | Catheter, ureteral | <1% | 45 | $21.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 28 | $20.10 |
| 80320 | <1% | 1,440 | $20.00 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 221 | $18.89 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 963 | $17.95 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 555 | $17.63 |
| S0028 | Injection, famotidine, 20 mg | <1% | 50 | $14.44 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 34 | $14.21 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 910 | $7.64 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 186 | $6.67 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 638 | $5.36 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 47 | $4.68 |
| 82272 | <1% | 147 | $3.34 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 79 | $2.18 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 370 | $1.51 |
| 92015 | Determination of refractive state | 0% | 40 | $0.00 |
| 99080 | 0% | 4,779 | $0.00 | |
| J7070 | Infusion, d5w, 1000 cc | 0% | 18 | $0.00 |
| 88302 | 0% | 76 | $0.00 | |
| 95712 | 0% | 28 | $0.00 | |
| J7627 | Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg | 0% | 264 | $0.00 |
| 80329 | 0% | 1,502 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 49 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 12 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 127 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 136 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIE, GARY (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| University Hospital at Stony Brook | Southampton, NY | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.